2024

EnterpriseWorks Media Mentions Recognition & Awards Research Park

Forbes: EnterpriseWorks Incubator Critical to Hypercell’s Startup Success

Forbes examines the “secret sauce” for EnterpriseWorks startup Hypercell Technologies‘ success – partnering with leading universities such as University of Illinois Urbana-Champaign and its award-winning incubator. The proximity to other startups in the EnterpriseWorks ecosystem fueled discovery and the building of community. “Partnering with the University of Illinois at Champaign-Urbana has provided Hypercell with immense support, including access to low-cost lab supplies (due to the University buying power), access to shared lab equipment (avoiding major capital investments), access to a wide array of scientific experts (both University and other start-up company staff), and a very effective incubator program at EnterpriseWorks which included training programs, support for government grants and assistance with hiring,” shares Hypercell’s co-founder and CEO Bruno Jactel in Forbes. EnterpriseWorks provided meaningful partnerships, state-of-the-art lab facilities, and mentor opportunities for Hypercell. Above all, the incubator offers camaraderie, allowing entrepreneurs to learn from each other’s successes and failures. “We’ve been a great peer community of entrepreneurs and technology experts working together and sharing their experiences and expertise,” says Laura Appenzeller, executive director of the University of Illinois Research Park. “That type of innovation community fuels new discovery and better outcomes for translational science.” Hypercell recently received the top prize of $1 million in funding and strategic mentorship at the 2023 Grow-NY Business Competition, a food and agriculture startup challenge. Read the entire Forbes article online here.

Forbes: EnterpriseWorks Incubator Critical to Hypercell’s Startup Success Read Post »

EnterpriseWorks Recognition & Awards Research Park

EnterpriseWorks Startup SimBioSys Receives FDA Clearance

EnterpriseWorks startup SimBioSys received a milestone FDA clearance for its foundational digital precision medicine technology, TumorSight™, enabling expansion to future cutting-edge applications. SimBioSys is unlocking the power of spatial biophysics with artificial intelligence (AI) and biophysical modeling to redefine precision medicine for cancer. TumorSight™ Viz utilizes standard-of-care medical imaging (DCE MRI) to generate stunning 3D spatial visualization and key insights, giving clinicians and their patients a more comprehensive understanding of their cancer and the potential options available to them. The technology utilizes AI to automatically segment the tumor and surrounding tissue to display the 3D visualization. Further, this TumorSight™ software application provides key insights such as tumor volume, tumor-to-breast volume, and tumor distance to key anatomical structures in the breast to quantify key metrics required in treatment planning. This is the company’s first FDA 510(k)-cleared device from its pipeline of products. “This is a landmark moment for the SimBioSys team and our many collaborators. It is our springboard to begin fulfilling our mission to redefine precision medicine as we launch this first application and target further expansion in clinical utilities within breast cancer as well as across other solid tumors,” says Tushar Pandey, co-founder and CEO of SimBioSys. Receiving FDA clearance is an exciting milestone as it paves the way to begin to delivering personalized and holistic support to clinicians and patients on the cancer care journey, redefining precision medicine and revolutionizing patient care. The company was founded in 2018 by researchers at the University of Illinois Urbana-Champaign to explore the intersection between AI and biophysical simulations in oncology.

EnterpriseWorks Startup SimBioSys Receives FDA Clearance Read Post »